Can MLH1 and MSH2 Mutations Be Targeted for Cancer Treatment?
Recent advances in cancer treatment explore targeting tumors with deficient MMR systems. Immunotherapy, particularly immune checkpoint inhibitors, has shown promise in treating cancers with high MSI due to MLH1 or MSH2 mutations. These therapies enhance the immune system's ability to recognize and destroy cancer cells, offering new hope for patients with tumors that are otherwise resistant to conventional treatments.
